Katarina Sjögreen Gleisner
1 – 10 of 69
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Dosimetric quantities of neuroendocrine tumors over treatment cycles with 177Lu-DOTA-TATE
(
- Contribution to journal › Article
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
(
- Contribution to journal › Article
-
Mark
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
(
- Contribution to journal › Article
-
Mark
Monte Carlo modelling of a compact CZT-based gamma camera with application to 177Lu imaging
(
- Contribution to journal › Article
-
Mark
Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
(
- Contribution to journal › Article
-
Mark
Properties of the Digital Image
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Activity Quantification from Planar Images
(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2021
-
Mark
A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT/CT imaging performed within the MRTDosimetry project
(
- Contribution to journal › Article
-
Mark
Pituitary function after high-dose 177Lu-DOTATATE therapy and long-term follow-up
(
- Contribution to journal › Article
-
Mark
Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment
(
- Contribution to journal › Article